An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Pevonedistat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda Oncology
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Apr 2012 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.